Document is current
Any future updates will be listed below
-
Authors
Grebinoski, Stephanie https://orcid.org/0000-0002-3562-3190
Zhang, Qianxia https://orcid.org/0000-0002-2885-2147
Cillo, Anthony R. https://orcid.org/0000-0002-3213-3129
Manne, Sasikanth
Xiao, Hanxi
Brunazzi, Erin A.
Tabib, Tracy
Cardello, Carly
Lian, Christine G.
Murphy, George F.
Lafyatis, Robert
Wherry, E. John https://orcid.org/0000-0003-0477-1956
Das, Jishnu https://orcid.org/0000-0002-5747-064X
Workman, Creg J. https://orcid.org/0000-0002-9964-9509
Vignali, Dario A. A. https://orcid.org/0000-0002-2771-5992
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK089125)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI144422, AI108545, AI147638, AI089443, AI105343, AI117950, AI082630, AI112521, AI115712, AI108545)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (CA210944)
- License Information
-
More Information
Article History
Received: 2 March 2022
Accepted: 12 April 2022
First Online: 26 May 2022
Competing interests
: D.A.A.V. and C.J.W. declare competing financial interests and have submitted patents covering LAG3 that are licensed or pending and are entitled to a share in net income generated from licensing of these patent rights for commercial development. D.A.A.V. is cofounder and stock holder of Novasenta, Potenza, Tizona and Trishula; stock holder of Oncorus, Werewolf and Apeximmune; has patents licensed and royalties from Astellas, BMS, Novasenta; scientific advisory board member of Tizona, Werewolf, F-Star, Bicara, Apeximmune and T7/Imreg Bio; is a consultant for Astellas, BMS, Almirall, Incyte, G1 Therapeutics and Inzen Therapeutics; and obtained research funding from BMS, Astellas and Novasenta. E.J.W. has consulting agreements with and/or is on the scientific advisory board for Merck, Roche, Pieris, Elstar and Surface Oncology. E.J.W. has a patent licensing agreement on the PD1 pathway with Roche/Genentech. E.J.W. is a founder of Arsenal Biosciences. The other authors declare no competing interests.
